JPMorgan Chase & Co. Has Lowered Expectations for Cooper Companies (NASDAQ:COO) Stock Price

Cooper Companies (NASDAQ:COO) had its price target cut by stock analysts at JPMorgan Chase & Co. from $71.00 to $58.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has a “neutral” rating on the medical device company’s stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 5.66% from the stock’s previous close.

Other equities analysts have also issued research reports about the stock. Bank of America reiterated a “neutral” rating and set a $65.00 price objective (down from $80.00) on shares of Cooper Companies in a report on Thursday. Needham & Company LLC decreased their target price on Cooper Companies from $86.00 to $73.00 and set a “buy” rating for the company in a research report on Thursday. BNP Paribas Exane dropped their price target on Cooper Companies from $95.00 to $92.00 and set an “outperform” rating on the stock in a research note on Monday, June 8th. KeyCorp reiterated a “sector weight” rating on shares of Cooper Companies in a report on Friday, June 5th. Finally, William Blair restated a “market perform” rating on shares of Cooper Companies in a report on Thursday. Five analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $73.47.

Cooper Companies Trading Down 13.5%

Shares of COO stock traded down $8.59 during trading hours on Thursday, hitting $54.89. 6,560,720 shares of the company were exchanged, compared to its average volume of 2,372,654. The company has a 50 day simple moving average of $72.42 and a two-hundred day simple moving average of $70.02. The firm has a market cap of $10.71 billion, a P/E ratio of 46.70, a P/E/G ratio of 1.77 and a beta of 0.82. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.78 and a current ratio of 1.27. Cooper Companies has a fifty-two week low of $51.01 and a fifty-two week high of $89.83.

Cooper Companies (NASDAQ:COO) last released its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.03. The company had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.10 billion. Cooper Companies had a net margin of 5.57% and a return on equity of 10.88%. Cooper Companies’s quarterly revenue was up .5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Equities analysts anticipate that Cooper Companies will post 4.63 EPS for the current year.

Cooper Companies declared that its Board of Directors has initiated a stock buyback plan on Wednesday, September 9th that authorizes the company to buyback $3.00 billion in outstanding shares. This buyback authorization authorizes the medical device company to reacquire up to 22.7% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

Institutional Investors Weigh In On Cooper Companies

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Algert Global LLC bought a new stake in shares of Cooper Companies in the 2nd quarter worth $7,655,000. BlackRock Inc. bought a new position in shares of Cooper Companies during the second quarter valued at about $1,077,762,000. Heartland Advisors Inc. bought a new position in shares of Cooper Companies during the fourth quarter valued at about $15,348,000. Tocqueville Asset Management L.P. purchased a new position in Cooper Companies during the second quarter worth about $1,502,000. Finally, Western Standard LLC purchased a new position in Cooper Companies during the second quarter worth about $5,228,000. 24.39% of the stock is owned by hedge funds and other institutional investors.

Cooper Companies News Summary

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: COO reported fiscal Q3 adjusted EPS of $1.15, above the $1.11-$1.12 analyst consensus. GAAP EPS was $2.24, helped by a $307.2 million benefit from the favorable completion of a U.K. tax examination. Free cash flow increased 66% to $273 million. CooperCompanies Announces Third Quarter 2026 Results
• Positive Sentiment: The board expanded the share-repurchase authorization from $2 billion to $3 billion, potentially allowing repurchases of up to 22.7% of outstanding shares. Management also said it remains open to strategic alternatives that could create shareholder value. CooperCompanies Completes Strategic Review
• Neutral Sentiment: Third-quarter revenue rose roughly 1% year over year to $1.066 billion, with CooperVision revenue flat at $717 million and CooperSurgical revenue up 2% to $349.2 million. The results show continued profitability but limited underlying growth.
• Negative Sentiment: Revenue missed the approximately $1.10 billion consensus estimate, while fiscal 2026 adjusted EPS guidance was cut to $4.51-$4.55 from expectations near $4.63. Fourth-quarter EPS guidance of $1.05-$1.09 also trails the roughly $1.20 consensus. Analysts Lower Forecasts Following Q3 Results
• Negative Sentiment: CooperCompanies ended its strategic review by retaining CooperSurgical because potential offers were not attractive enough. Investors appear disappointed that the company will not receive sale proceeds, amid valuation pressure from a new non-hormonal IUD competitor and recent fertility-litigation costs.
• Negative Sentiment: Analysts responded by lowering price targets, including Needham to $73 from $86 and Bank of America to $65 from $80. Bank of America maintained a neutral rating, while the forecast reductions reinforced concerns about near-term growth.

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.